Britain's GSK has agreed to buy RAPT Therapeutics for $2.2 billion, accessing the U.S. biotech's experimental drug to treat ...

The growing scourge of food allergies drove U.K. heavyweight pharmaceutical GSK to announce a $2.2 billion deal on Tuesday.

GSK will acquire RAPT Therapeutics for $2.2 billion to gain ozureprubart, a promising food allergy drug that could treat over ...

GSK is staking billions on a new way to protect people from life‑threatening food allergies, agreeing to buy RAPT ...

If that’s not an option, consult the Food and Drug Administration’s “flush list” to see if a medicine can be safely flushed ...

GSK acquires Rapt Therapeutics for $2.2B. Stock surges 65% as pharma giant gains access to phase 2b food allergy treatment ...

There are currently "several serious data gaps" limiting the FDA's ability to know the adverse reactions to gluten in ...

That price equates to an aggregate equity value of $2.2 billion, according to GSK, who added that the upfront investment net ...

The deal is the first for new CEO Luke Miels as the British drugmaker looks to overcome pressure on its HIV and vaccines ...

RAPT Therapeutics, Inc. is being acquired by GSK plc for $2.2B as ozureprubart targets IgE disorders with 8–12 week dosing.

Drug-induced fever can complicate antibiotic treatment and lead to unnecessary testing when cultures are negative, and ...

The drugmaker said it agreed to pay RAPT Therapeutics shareholders $58 per share, with $1.9 billion upfront investment in ...